Cell & Gene Therapies

A broad shift in the gene therapy space impacts demand for viral vectors. Pic: getty/yourphoto

Why viral vector manufacturing capacity is constrained

By Nick Taylor

Viral vector production capacity has become increasingly constrained in recent years due to increases in the therapies in development, the dosages given and the patient populations targeted. COVID-19 is exacerbating the situation.

AGTC's clinical pipeline is focused on rare genetic eye diseases, but is expanding. Pic:getty/drpas

Using HSV helper viruses to increase AAV production

By Nick Taylor

Recognizing the industry-wide need to improve adeno-associated virus (AAV) vector manufacturing, Applied Genetic Technologies Corporation (AGTC) has adopted changes intended to increase yield and purity.

© GettyImages/ipopba

Cytiva invests for global capacity expansion

By Jane Byrne

Cytiva is to invest US$500m over the next five years to raise manufacturing capacity, hiring nearly 1,000 personnel in Austria, China, Singapore, Sweden, and the US, and bringing on new manufacturing lines, 24/7 shift patterns, and increased automation.

© GettyImages/metamorworks

FDA calls for more data on Sarepta gene therapy for DMD

By Jane Byrne

An FDA regulatory request to Sarepta could delay the timeline for approval of its Duchenne muscular dystrophy (DMD) gene therapy if it results in a deferral of the start of a planned Phase 3 study for SRP-9001.

© GettyImages/chaluk

Reducing barriers to mainstream gene therapy

By Jane Byrne

AskBio, which develops adeno-associated virus (AAV) gene therapies for genetic disorders, has won an R&D grant valued at £2m (around US$2.7m) from Scottish Enterprise.

Follow us

Products

View more

Webinars